title: Tetrabenazine treatment in movement disorders.
abstract: Tetrabenazine (TBZ) is a catecholamine depletor used for the treatment of a variety of movement disorders. The purpose of this study was to assess the efficacy of TBZ in a retrospective chart review in 3 tertiary care movement disorders centers over long-term treatment. Of 150 patients to whom TBZ was prescribed, 118 were followed up and assessed using the Clinical Global Impression of Change (CGIC), (-3 to +3), a composite grade from a patient and caregiver scale over variable periods. The patients had a variety of hyperkinetic movement disorders including dystonia (generalized and focal: axial, Meige syndrome, torticollis, blepharospasm, bruxism), Huntington disease (HD) or other choreas, tardive dyskinesia (TD) or akathisia, and Tourette syndrome. Mean patient age was 48.8 +/- 18.7 years; 48 were men (40.7%) with a mean disease duration of 93 months. The mean follow-up time was 22 months and the mean TBZ dose was 76.2 +/- 22.5 mg/d (median 75 mg, range 25-175 mg/d). The mean CGIC score was +1 (mild improvement). The group of patients who scored +3 on the CGIC (very good improvement) represented 18.6% (n = 22) of all patients. They had HD or other types of chorea 7.6% (n = 9), facial dystonia/dyskinesia (n = 7, 5.9%), 1 with TD, 2 with trunk dystonia, 2 with Tourette syndrome, and 1 with tardive akathisia. This group had the longest treatment duration and received a mean TBZ dose of 70.5 mg/d (median 75 mg/d) for a mean of 25.4 +/- 21.3 months. The report concludes that TBZ is a moderately effective treatment of a large variety of hyperkinetic movement disorders, with excellent effects in a subgroup with chorea and facial dystonia/dyskinesias.
authors.affiliation: Neurology Service and Memory Clinic, Abarbanel Mental Health Center, Bat-Yam, affiliated to the Sackler School of Medicine, Tel Aviv University, Israel. paleacu@post.tau.ac.il
authors.forename: D
authors.initials: D
authors.lastname: Paleacu
authors.forename: N
authors.initials: N
authors.lastname: Giladi
authors.forename: O
authors.initials: O
authors.lastname: Moore
authors.forename: A
authors.initials: A
authors.lastname: Stern
authors.forename: S
authors.initials: S
authors.lastname: Honigman
authors.forename: S
authors.initials: S
authors.lastname: Badarny
mesh_terms: D000328:Adult; D018726:Anti-Dyskinesia Agents / Q000009:adverse effects / Q000627:therapeutic use*; D002819:Chorea / Q000188:drug therapy; D004305:Dose-Response Relationship, Drug; D005260:Female; D019569:Hemifacial Spasm / Q000188:drug therapy; D006801:Humans; D006948:Hyperkinesis / Q000188:drug therapy / Q000503:physiopathology; D008297:Male; D009069:Movement Disorders / Q000188:drug therapy* / Q000503:physiopathology; D013747:Tetrabenazine / Q000009:adverse effects / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D018726:Anti-Dyskinesia Agents; D013747:Tetrabenazine